Between 2020 and 2024, not a single woman aged 20 to 24 in England died from cervical cancer. That is the striking finding from a new study published in The Lancet, offering the most compelling evidence yet that national HPV vaccination programs are working.

Researchers at Queen Mary University of London analyzed mortality data alongside vaccine coverage records. They found that for women who received the HPV vaccine between the ages of 12 and 18, cervical cancer deaths plummeted by 80 percent between 2015 and 2019. By 2020, that number hit zero. It is a milestone in public health.

The Power of Early Intervention

The Human Papillomavirus (HPV) is the most common sexually transmitted infection globally. While most infections clear on their own, certain high-risk strains cause nearly all cervical cancer cases. England’s school-based vaccination program, launched in the mid-2000s, targeted adolescent girls specifically to block these infections before exposure.

The results have been profound. The program led to a 90 percent drop in HPV infections among adolescents. This success has put the country on a clear trajectory toward its goal: eliminating cervical cancer as a public health problem by 2040.

Why Context Matters

While the data is encouraging, experts urge caution. Dr. Allison Portnoy, an assistant professor at Boston University School of Public Health, noted in an invited commentary that the study relies on population-level data. It does not track individual health outcomes.

Other factors likely contributed to the decline. Expanded cervical cancer screening programs and the effects of herd immunity—where vaccinated individuals reduce the overall transmission of the virus—played significant roles. The vaccine is not a standalone solution. It is part of a broader infrastructure.

The Road Ahead

We are still in the early stages. The vaccinated cohorts are relatively young, and the risk of cervical cancer increases with age. As these women move into their 30s and 40s, researchers will need to monitor whether this protective effect persists.

Different HPV genotypes may also pose new challenges as populations age. The next phase of research will require individual-level data to confirm a direct cause-and-effect link. For now, the England data serves as a critical benchmark for other nations.

Key Takeaways

  • Zero Mortality: No cervical cancer deaths were recorded between 2020 and 2024 among vaccinated women aged 20–24 in England.
  • Population Impact: The study suggests an 80 percent decline in mortality during the preceding five-year period, likely driven by high vaccine coverage.
  • Multifaceted Strategy: Success is attributed to a combination of early vaccination, robust screening infrastructure, and herd immunity.

What Experts Say

Researchers emphasize that these gains are not guaranteed globally. In low-income countries, where HPV rates are highest, access to vaccines remains limited. The challenge is no longer just proving the vaccine works. It is ensuring the infrastructure exists to deliver it equitably.

As countries continue to gather long-term data, the focus must shift toward sustaining these programs. The next major decision point for health officials will arrive when the first vaccinated cohorts reach the age where cervical cancer risk typically accelerates. By 2030, we will have enough data to know if the current protection holds firm against the full spectrum of HPV genotypes.